Sanara MedTechSMTI
SMTI
About: Sanara MedTech Inc is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the chronic and surgical wound and skincare markets. Its portfolio of products and services allows it to deliver comprehensive wound and skincare solutions for patients in all care settings, including acute and post-acute. Its surgical wound care products are CellerateRX Surgical Activated Collagen. Its chronic wound care products are BIAKOS Skin and Wound Cleanser, and BIAKOS Skin and Wound Gel.
Employees: 141
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
0.61% less ownership
Funds ownership: 10.9% [Q4 2024] → 10.3% (-0.61%) [Q1 2025]
4% less funds holding
Funds holding: 51 [Q4 2024] → 49 (-2) [Q1 2025]
11% less capital invested
Capital invested by funds: $31.6M [Q4 2024] → $28.3M (-$3.35M) [Q1 2025]
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
40% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 20
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$46
60%
upside
Avg. target
$50
72%
upside
High target
$53
84%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Yi Chen | 84%upside $53 | Buy Maintained | 15 May 2025 |
Cantor Fitzgerald Ross Osborn | 60%upside $46 | Overweight Reiterated | 26 Mar 2025 |
Financial journalist opinion
Neutral
Seeking Alpha
5 days ago
Sanara MedTech: Pursuing Rapid Expansion While Debt Levels Climb
Sanara MedTech's surgical revenue grew 26% year-over-year in Q1, with a gross margin of 92%. Surgical adjusted EBITDA was $2.7 million in Q1, while THP correspondingly posted a loss of $2 million. High debt levels and elevated interest expenses are key risks, along with the uncertainty surrounding the commercialization of THP.
Neutral
Seeking Alpha
1 month ago
Sanara MedTech Inc. (SMTI) Q1 2025 Earnings Call Transcript
Sanara MedTech Inc. (NASDAQ:SMTI ) Q1 2025 Earnings Conference Call May 14, 2025 8:00 AM ET Company Participants Ron Nixon - Executive Chairman, Chief Executive Officer Seth Yon - President, Chief Commercial Officer Sam Muppalla - President, Chief Executive Officer of Tissue Health Plus Elizabeth Taylor - Chief Financial Officer Conference Call Participants Matt Park - Cantor Fitzgerald Operator Welcome to the Sanara MedTech First Quarter of 2025 Earnings Conference Call. Please note that this conference call is being recorded and a replay will be available on the Investor Relations page of the company's website shortly.
Negative
Zacks Investment Research
1 month ago
Sanara MedTech Inc. (SMTI) Reports Q1 Loss, Tops Revenue Estimates
Sanara MedTech Inc. (SMTI) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.21 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
Sanara MedTech Inc. Reports First Quarter 2025 Financial Results (Unaudited)
Q1 Net Revenue Increased 26% Year-Over-Year FORT WORTH, TX, May 14, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, today reported its financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Summary ● Net revenue increased 26% to $23.4 million, compared to $18.5 million in the first quarter of 2024.
Neutral
GlobeNewsWire
1 month ago
Sanara MedTech to Report First Quarter 2025 Financial Results on May 14, 2025
FORT WORTH, TX, April 23, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc . (“Sanara,” or the “Company”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, today announced it will report its first quarter 2025 financial results on Wednesday, May 14, 2025 before the U.S. financial markets open.
Neutral
GlobeNewsWire
2 months ago
Sanara MedTech to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025
FORT WORTH, TX, April 10, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, announced today that management will present at the Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub, which is being held at the Paris Hotel & Casino in Las Vegas, NV from April 22 – 25, 2025. Management will deliver a presentation to investors on Wednesday, April 23 at approximately 3:30 p.m. Pacific Time.
Positive
Zacks Investment Research
2 months ago
Sanara MedTech (SMTI) Stock Jumps 8.1%: Will It Continue to Soar?
Sanara MedTech (SMTI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Neutral
Seeking Alpha
2 months ago
Sanara MedTech Inc. (SMTI) Q4 2024 Earnings Call Transcript
Sanara MedTech Inc. (NASDAQ:SMTI ) Q4 2024 Earnings Conference Call March 25, 2025 8:00 AM ET Company Participants Ron Nixon - Executive Chairman and Chief Executive Officer Seth Yon - President, Commercial Sam Muppalla - Tissue Health Plus Tyler Palmer - Chief Corporate Development and Strategy Officer Elizabeth Taylor - Chief Financial Officer Conference Call Participants Ross Osborn - Cantor Fitzgerald Operator Good day, and welcome to the Sanara MedTech Fourth Quarter and Full-Year 2024 Earnings Conference Call. Please not that this conference call is being recorded and a replay will be available on the investor relations page of the company's website shortly.
Neutral
GlobeNewsWire
2 months ago
Sanara MedTech Inc. Reports Fourth Quarter and Full Year 2024 Financial Results (Unaudited)
Q4 Net Revenue Increased 49% Year-Over-Year; 2024 Net Revenue Increased 33% Year-Over-Year FORT WORTH, TX, March 25, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, today reported its financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Financial Summary ● Net revenue increased 49% to $26.3 million, compared to $17.7 million in the fourth quarter of 2023.
Neutral
GlobeNewsWire
3 months ago
Sanara MedTech to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025
FORT WORTH, TX, March 11, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc . (“Sanara,” or the “Company”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, today announced it will report its fourth quarter and full year 2024 financial results on Tuesday, March 25, 2025 before the U.S. financial markets open.
Charts implemented using Lightweight Charts™